MARKET

CTXR

CTXR

Citius Pharmaceuticals Inc
NASDAQ
0.8973
+0.0732
+8.88%
After Hours: 0.9099 +0.0126 +1.40% 19:57 03/28 EDT
OPEN
0.8100
PREV CLOSE
0.8241
HIGH
0.9303
LOW
0.8050
VOLUME
1.28M
TURNOVER
0
52 WEEK HIGH
1.710
52 WEEK LOW
0.6000
MARKET CAP
142.76M
P/E (TTM)
-3.5188
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CTXR last week (0318-0322)?
Weekly Report · 4d ago
Positive Outlook for Citius Pharmaceuticals with Lymphir’s FDA Resubmission and Market Potential
TipRanks · 03/20 17:25
Citius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatment
Healthcare Citius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatment. LYMPHIR is an IL-2-based immunotherapy for the treatment of patients with relapsed or refractory T-cell lymphoma. The FDA has assigned a PDUFA goal date of August 13, 2024.
Seeking Alpha · 03/18 13:26
Citius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick Facts
NASDAQ · 03/18 13:05
Weekly Report: what happened at CTXR last week (0311-0315)?
Weekly Report · 03/18 11:52
Weekly Report: what happened at CTXR last week (0304-0308)?
Weekly Report · 03/11 11:48
Citius Pharmaceuticals Secures $2.4M Through New Jersey Economic Development Program
Benzinga · 03/07 13:35
Weekly Report: what happened at CTXR last week (0226-0301)?
Weekly Report · 03/04 11:51
More
About CTXR
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.

Webull offers Citius Pharmaceuticals Inc stock information, including NASDAQ: CTXR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTXR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTXR stock methods without spending real money on the virtual paper trading platform.